BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19441900)

  • 1. New hexahydrodiazocino-naphthyridine triones as HIV-1 integrase inhibitors: WO2008048538 A1.
    Cotelle P
    Expert Opin Ther Pat; 2009 Jan; 19(1):87-93. PubMed ID: 19441900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.
    Cotelle P
    Expert Opin Ther Pat; 2011 Nov; 21(11):1799-804. PubMed ID: 21974685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.
    Melamed JY; Egbertson MS; Varga S; Vacca JP; Moyer G; Gabryelski L; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Hazuda DJ; Leonard Y; Jin L; Ellis JD; Young SD
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5307-10. PubMed ID: 18774711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells.
    Zhuang L; Wai JS; Embrey MW; Fisher TE; Egbertson MS; Payne LS; Guare JP; Vacca JP; Hazuda DJ; Felock PJ; Wolfe AL; Stillmock KA; Witmer MV; Moyer G; Schleif WA; Gabryelski LJ; Leonard YM; Lynch JJ; Michelson SR; Young SD
    J Med Chem; 2003 Feb; 46(4):453-6. PubMed ID: 12570367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors.
    Guare JP; Wai JS; Gomez RP; Anthony NJ; Jolly SM; Cortes AR; Vacca JP; Felock PJ; Stillmock KA; Schleif WA; Moyer G; Gabryelski LJ; Jin L; Chen IW; Hazuda DJ; Young SD
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2900-4. PubMed ID: 16554152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
    Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
    J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore.
    Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1802-6. PubMed ID: 19217781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position.
    Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1807-10. PubMed ID: 19217284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
    Cabrera C
    Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties.
    Zeng LF; Wang Y; Kazemi R; Xu S; Xu ZL; Sanchez TW; Yang LM; Debnath B; Odde S; Xie H; Zheng YT; Ding J; Neamati N; Long YQ
    J Med Chem; 2012 Nov; 55(22):9492-509. PubMed ID: 23098137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1.
    Zhao XZ; Smith SJ; Métifiot M; Marchand C; Boyer PL; Pommier Y; Hughes SH; Burke TR
    J Med Chem; 2014 Jun; 57(12):5190-202. PubMed ID: 24901667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.
    Hazuda DJ; Anthony NJ; Gomez RP; Jolly SM; Wai JS; Zhuang L; Fisher TE; Embrey M; Guare JP; Egbertson MS; Vacca JP; Huff JR; Felock PJ; Witmer MV; Stillmock KA; Danovich R; Grobler J; Miller MD; Espeseth AS; Jin L; Chen IW; Lin JH; Kassahun K; Ellis JD; Wong BK; Xu W; Pearson PG; Schleif WA; Cortese R; Emini E; Summa V; Holloway MK; Young SD
    Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11233-8. PubMed ID: 15277684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV integrase inhibitors.
    Boros EE; Edwards CE; Foster SA; Fuji M; Fujiwara T; Garvey EP; Golden PL; Hazen RJ; Jeffrey JL; Johns BA; Kawasuji T; Kiyama R; Koble CS; Kurose N; Miller WH; Mote AL; Murai H; Sato A; Thompson JB; Woodward MC; Yoshinaga T
    J Med Chem; 2009 May; 52(9):2754-61. PubMed ID: 19374386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors.
    Ravichandran V; Shalini S; Sundram K; Sokkalingam AD
    Eur J Med Chem; 2010 Jul; 45(7):2791-7. PubMed ID: 20347187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors.
    Jin H; Cai RZ; Schacherer L; Jabri S; Tsiang M; Fardis M; Chen X; Chen JM; Kim CU
    Bioorg Med Chem Lett; 2006 Aug; 16(15):3989-92. PubMed ID: 16723225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent and orally active HIV-1 integrase inhibitor.
    Egbertson MS; Moritz HM; Melamed JY; Han W; Perlow DS; Kuo MS; Embrey M; Vacca JP; Zrada MM; Cortes AR; Wallace A; Leonard Y; Hazuda DJ; Miller MD; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Gabryelski LJ; Moyer G; Ellis JD; Jin L; Xu W; Braun MP; Kassahun K; Tsou NN; Young SD
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1392-8. PubMed ID: 17194584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.
    Embrey MW; Wai JS; Funk TW; Homnick CF; Perlow DS; Young SD; Vacca JP; Hazuda DJ; Felock PJ; Stillmock KA; Witmer MV; Moyer G; Schleif WA; Gabryelski LJ; Jin L; Chen IW; Ellis JD; Wong BK; Lin JH; Leonard YM; Tsou NN; Zhuang L
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4550-4. PubMed ID: 16102965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors.
    Nagasawa JY; Song J; Chen H; Kim HW; Blazel J; Ouk S; Groschel B; Borges V; Ong V; Yeh LT; Girardet JL; Vernier JM; Raney AK; Pinkerton AB
    Bioorg Med Chem Lett; 2011 Jan; 21(2):760-3. PubMed ID: 21185178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.